Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Gains from Sales and Divestitures (2020 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 22.08% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 22.08% decrease, with the full-year FY2024 number at $1.3 million, down 14.67% from a year prior.
  • Gains from Sales and Divestitures was $1.2 million for Q3 2025 at Xtant Medical Holdings, up from $386624.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.5 million in Q4 2023 to a low of $22245.0 in Q1 2023.
  • A 5-year average of $611811.6 and a median of $349572.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 90.91% in 2023, then surged 539.82% in 2024.
  • Xtant Medical Holdings' Gains from Sales and Divestitures stood at $782596.0 in 2021, then surged by 91.72% to $1.5 million in 2022, then grew by 2.39% to $1.5 million in 2023, then decreased by 14.67% to $1.3 million in 2024, then fell by 11.91% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Gains from Sales and Divestitures are $1.2 million (Q3 2025), $386624.0 (Q2 2025), and $44496.0 (Q1 2025).